RxDoctor Payments Data

Randall Blake, MD

Urology · Honolulu, HINPI 1447226055

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Johnson & Johnson at 51.8% of the total. Reporting peaked in 2019 at $286 and has fallen 90.9% since, to $26 in 2025. That places this record below the midpoint for urology clinicians in HI, where the typical reported total is $937.

$933in general payments, 2019–2025

Across 30 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$483
  • Astellas Pharma US Inc$292
  • Pfizer$53
  • Bayer$30
  • AbbVie$26
  • Teleflex LLC$25
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$52556%
  • Education$40844%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$933 in reported general payments places this provider in the 45th percentile of 46 urology providers in Hawaii.

See all urology providers in Hawaii

Medicare billing

Part B allowed, 2024
$95,520
Medicare patients
406
Services billed
1,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide12$174,317
EligardLeuprolide Acetate23$32,271
MyrbetriqMirabegron31$22,730
Finasteride253$8,077
Tamsulosin Hcl211$4,615
Potassium Citrate ErPotassium Citrate38$4,066
Oxybutynin Chloride ErOxybutynin Chloride47$3,372
Methenamine Hippurate16$1,737
Bicalutamide28$1,389
Dutasteride19$1,336
NitrofurantoinNitrofurantoin Macrocrystal17$589
Allopurinol21$391
Testosterone Cypionate12$222
Ciprofloxacin Hcl33$148
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$483$174,31712 claims
Astellas Pharma US IncMyrbetriq$292$22,73031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 46 urology providers in Hawaii.

Other urology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →